Developer docs
API playgroundTry for free, no card

Search company profiles

Blaze Bioscience

Full company profile

uuid0000if4

Namestring
Blaze Bioscience
Legal namestring
Blaze Bioscience, Inc.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Blaze Bioscience, Inc. is a Seattle-based, privately held biotechnology company founded in 2010 that develops and intends to commercialize products enabling surgeons to visualize tumor tissue in real time during cancer surgery. Its core platform, Tumor Paint®, pairs tozuleristide (BLZ-100), an investigational fluorescent imaging agent built from a chlorotoxin–indocyanine green conjugate, with the CANVAS® imaging system to highlight malignant tissue under near-infrared light during resection. The intended use cases include achieving clear margins in breast-conserving surgery, glioma resection, head and neck squamous cell carcinoma, and skin cancer procedures. The lead clinical program targets pediatric central nervous system tumors, where the FDA granted Fast Track Designation in April 2020 and the pivotal Phase 2/3 trial completed enrollment in November 2022; Phase 1 data have been published in peer-reviewed journals including Archives of Pathology & Laboratory Medicine, Neurosurgery, JAMA Otolaryngology, and Cancer Research.

The company is pre-revenue and does not yet have an approved product or an active Expanded Access Program. The future revenue model combines pharmaceutical product sales to hospitals and surgical centers (planned via a specialized field sales force following FDA approval) with potential technology licensing and royalty arrangements, and the company has publicly opened a partnering channel to expand Tumor Paint applications into cancer surgery, high-risk surveillance, and screening. Capital formation has been sustained through multiple venture rounds totaling roughly $55 million between 2012 and 2019, including a $5 million raise in February 2019, supporting clinical development and CMC infrastructure. Leadership is led by President and CEO Steven Daly, with scientific founder James Olson, MD, PhD (Seattle Children's / Fred Hutchinson Cancer Research Center) anchoring the scientific credibility of the platform.

Customer concentration is undefined commercially because no product is approved; the company's operating geographies are described as the United States, with headquarters at 530 Fairview Avenue North, Suite 1400, Seattle, Washington, and an 11–50 employee footprint. Blaze has no disclosed AI/ML capabilities and relies on its proprietary fluorescent chemistry and intraoperative imaging hardware as the source of competitive differentiation rather than on data-driven or model-based analytics.

Short descriptiontext

Blaze Bioscience is a Seattle-based, privately held clinical-stage biotech developing Tumor Paint® (tozuleristide) and the CANVAS® imaging system to give surgeons real-time intraoperative fluorescence visualization of tumor tissue during cancer resection procedures.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fluorescent imaging agents, intraoperative tumor visualization, cancer surgery technology, biopharmaceutical imaging drugs, clinical stage biotechnology
Industry3 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAKAFAG
Surgical Oncology
SECONDARYHLAKAFAH
Neuro-Oncology
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Surgical Oncology Imaging
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical stage biotech company. Future revenue expected from sale of tozuleristide (BLZ-100) as a fluorescent tumor visualization agent for cancer surgery. The product will be sold to hospitals and surgical centers for use during tumor resection procedures.

blazebioscience.com
2Technology Licensing
TypeLicensing Royalties
Description

The company holds proprietary Tumor Paint® technology and CANVAS® imaging system. Potential for licensing partnerships or collaborations to expand applications for cancer surgery, high-risk surveillance and screening.

blazebioscience.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Tumor Paint®
Description

Proprietary tumor visualization technology platform including tozuleristide (BLZ-100) for real-time intraoperative tumor detection

blazebioscience.com
+1 more record
Core offering1 text field

Blaze Bioscience develops and is commercializing Tumor Paint®, an investigational fluorescent imaging agent (tozuleristide / BLZ-100) that conjugates a scorpion-derived chlorotoxin peptide with indocyanine green (ICG) to make tumor tissue fluoresce under near-infrared light during surgery. The drug is administered to patients prior to surgery and visualized intraoperatively using the company's CANVAS® real-time fluorescence imaging system, allowing oncology surgeons to distinguish malignant tissue from healthy tissue, identify residual cancer on cavity walls, and improve achievement of clear margins in procedures such as breast-conserving surgery, brain tumor resection, and other solid-tumor operations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Real-time visualization of breast carcinoma in pathology specimens from patients receiving tozuleristide
+2 more records
Product overview1 text field

Blaze Bioscience is a biotechnology company developing Tumor Paint® technology, which consists of two integrated products: tozuleristide (BLZ-100), an investigational fluorescent tumor-targeting imaging agent, and the CANVAS® imaging system. These products work together to enable real-time intraoperative visualization of tumor tissue, allowing surgeons to see and remove cancer during the initial surgery while distinguishing malignant tissue from healthy tissue.

Product and service2 records
1Tumor Paint® (tozuleristide / BLZ-100)
CategorySurgical oncology imaging agent
Description

Investigational fluorescent imaging agent composed of a chlorotoxin peptide conjugated to indocyanine green (ICG); administered to patients prior to surgery so that tumor tissue fluoresces under near-infrared light and can be visualized in real time by surgeons, enabling distinction of tumor from healthy tissue and improved achievement of clear margins in cancer resection procedures.

2CANVAS® Imaging System
CategorySurgical imaging hardware
Description

Real-time intraoperative fluorescence imaging system used in conjunction with tozuleristide (BLZ-100) to visualize tumor tissue during cancer surgery, allowing surgeons to detect residual cancer on cavity walls and improve complete resection rates.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Blaze is actively seeking collaborations to expand applications of tozuleristide and Tumor Paint technology for cancer surgery, high-risk surveillance and screening. The company is open to partnerships that advance the clinical development and commercialization of their tumor visualization technology.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Lumicell develops an intraoperative fluorescence imaging system (Lumicell DVS) combined with a tumor-targeting imaging agent to detect residual cancer in real time during surgery — directly comparable mechanism and breast-cancer surgical use case as Blaze's Tumor Paint.

TypeDirect peer
Description

Perimeter develops wide-field optical coherence tomography and AI-driven image analysis for intraoperative margin assessment in breast-conserving surgery — competing in the same clinical workflow that Blaze's Tumor Paint targets.

3Avelas Biosciences
TypeEmerging player
Description

Avelas is developing fluorescent imaging agents for cancer surgery visualization, paralleling Blaze's Tumor Paint approach with a focus on tumor-targeted intraoperative fluorescence.

TypeBroad incumbent
Description

Stryker acquired Novadaq and now markets the SPY fluorescence imaging platform used in surgical visualization, making it a broad incumbent in intraoperative fluorescence imaging overlapping Blaze's clinical setting.

TypeBroad incumbent
Description

Karl Storz is a leading endoscopy and surgical imaging vendor with near-infrared fluorescence capabilities integrated into its visualization platforms — overlapping Blaze's intraoperative imaging use cases.

6Carl Zeiss Meditec
TypeBroad incumbent
Description

Zeiss Meditec supplies surgical microscopy and intraoperative fluorescence imaging solutions, including for neurosurgical oncology workflows directly comparable to tozuleristide's CNS tumor application.

TypeBroad incumbent
Description

Medtronic is a broad neurosurgery and surgical-tools incumbent with imaging-adjacent offerings relevant to the CNS tumor resection setting Blaze targets with its pediatric CNS pivotal program.

TypeOthers
Description

Leica manufactures surgical and fluorescence microscopy platforms used in operating-room visualization, making it an adjacent enabling technology provider to Blaze's intraoperative imaging approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blaze Bioscience

Surgical Oncology Imagingblazebioscience.com

Blaze Bioscience is a Seattle-based, privately held clinical-stage biotech developing Tumor Paint® (tozuleristide) and the CANVAS® imaging system to give surgeons real-time intraoperative fluorescence visualization of tumor tissue during cancer resection procedures.

What Blaze Bioscience does

Blaze Bioscience, Inc. is a Seattle-based, privately held biotechnology company founded in 2010 that develops and intends to commercialize products enabling surgeons to visualize tumor tissue in real time during cancer surgery. Its core platform, Tumor Paint®, pairs tozuleristide (BLZ-100), an investigational fluorescent imaging agent built from a chlorotoxin–indocyanine green conjugate, with the CANVAS® imaging system to highlight malignant tissue under near-infrared light during resection. The intended use cases include achieving clear margins in breast-conserving surgery, glioma resection, head and neck squamous cell carcinoma, and skin cancer procedures. The lead clinical program targets pediatric central nervous system tumors, where the FDA granted Fast Track Designation in April 2020 and the pivotal Phase 2/3 trial completed enrollment in November 2022; Phase 1 data have been published in peer-reviewed journals including Archives of Pathology & Laboratory Medicine, Neurosurgery, JAMA Otolaryngology, and Cancer Research.

The company is pre-revenue and does not yet have an approved product or an active Expanded Access Program. The future revenue model combines pharmaceutical product sales to hospitals and surgical centers (planned via a specialized field sales force following FDA approval) with potential technology licensing and royalty arrangements, and the company has publicly opened a partnering channel to expand Tumor Paint applications into cancer surgery, high-risk surveillance, and screening. Capital formation has been sustained through multiple venture rounds totaling roughly $55 million between 2012 and 2019, including a $5 million raise in February 2019, supporting clinical development and CMC infrastructure. Leadership is led by President and CEO Steven Daly, with scientific founder James Olson, MD, PhD (Seattle Children's / Fred Hutchinson Cancer Research Center) anchoring the scientific credibility of the platform.

Customer concentration is undefined commercially because no product is approved; the company's operating geographies are described as the United States, with headquarters at 530 Fairview Avenue North, Suite 1400, Seattle, Washington, and an 11–50 employee footprint. Blaze has no disclosed AI/ML capabilities and relies on its proprietary fluorescent chemistry and intraoperative imaging hardware as the source of competitive differentiation rather than on data-driven or model-based analytics.

Blaze Bioscience firmographics

Firmographics
Name
Blaze Bioscience
Legal name
Blaze Bioscience, Inc.
Website
https://blazebioscience.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Blaze Bioscience is a Seattle-based, privately held clinical-stage biotech developing Tumor Paint® (tozuleristide) and the CANVAS® imaging system to give surgeons real-time intraoperative fluorescence visualization of tumor tissue during cancer resection procedures.
Ownership category
akta.pro rank

Blaze Bioscience industry classification

Industry
Product category
Surgical Oncology Imaging
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAKAFAG
Surgical Oncology
SECONDARYHLAKAFAH
Neuro-Oncology

Keywords

  • Fluorescent imaging agents
  • Intraoperative tumor visualization
  • Cancer surgery technology
  • Biopharmaceutical imaging drugs
  • Clinical stage biotechnology

Where Blaze Bioscience is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Blaze Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical stage biotech company. Future revenue expected from sale of tozuleristide (BLZ-100) as a fluorescent tumor visualization agent for cancer surgery. The product will be sold to hospitals and surgical centers for use during tumor resection procedures.
  2. Technology Licensing: The company holds proprietary Tumor Paint® technology and CANVAS® imaging system. Potential for licensing partnerships or collaborations to expand applications for cancer surgery, high-risk surveillance and screening.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Blaze Bioscience product offering

Product offering

Core offering

Blaze Bioscience develops and is commercializing Tumor Paint®, an investigational fluorescent imaging agent (tozuleristide / BLZ-100) that conjugates a scorpion-derived chlorotoxin peptide with indocyanine green (ICG) to make tumor tissue fluoresce under near-infrared light during surgery. The drug is administered to patients prior to surgery and visualized intraoperatively using the company's CANVAS® real-time fluorescence imaging system, allowing oncology surgeons to distinguish malignant tissue from healthy tissue, identify residual cancer on cavity walls, and improve achievement of clear margins in procedures such as breast-conserving surgery, brain tumor resection, and other solid-tumor operations.

Product overview

Blaze Bioscience is a biotechnology company developing Tumor Paint® technology, which consists of two integrated products: tozuleristide (BLZ-100), an investigational fluorescent tumor-targeting imaging agent, and the CANVAS® imaging system. These products work together to enable real-time intraoperative visualization of tumor tissue, allowing surgeons to see and remove cancer during the initial surgery while distinguishing malignant tissue from healthy tissue.

Differentiator

Problem solved

Functional benefit

Brands

  • Tumor Paint®: Proprietary tumor visualization technology platform including tozuleristide (BLZ-100) for real-time intraoperative tumor detection
  • CANVAS®

Products and services

  • Tumor Paint® (tozuleristide / BLZ-100) Investigational fluorescent imaging agent composed of a chlorotoxin peptide conjugated to indocyanine green (ICG); administered to patients prior to surgery so that tumor tissue fluoresces under near-infrared light and can be visualized in real time by surgeons, enabling distinction of tumor from healthy tissue and improved achievement of clear margins in cancer resection procedures.
  • CANVAS® Imaging System Real-time intraoperative fluorescence imaging system used in conjunction with tozuleristide (BLZ-100) to visualize tumor tissue during cancer surgery, allowing surgeons to detect residual cancer on cavity walls and improve complete resection rates.

Quantifiable outcome

  • Real-time visualization of breast carcinoma in pathology specimens from patients receiving tozuleristide
  • +2 more outcomes

Companies that use Blaze Bioscience

Customer profile

Segments2 records

Ideal customer profiles1 record

Blaze Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Blaze Bioscience partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Collaborative Partners (Seeking)coreStrategic or Co-development PartnerBlaze is actively seeking collaborations to expand applications of tozuleristide and Tumor Paint technology for cancer surgery, high-risk surveillance and screening. The company is open to partnerships that advance the clinical development and commercialization of their tumor visualization technology.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Blaze Bioscience competitors and assessment

Company assessment

Direct peers

  • Lumicell: Lumicell develops an intraoperative fluorescence imaging system (Lumicell DVS) combined with a tumor-targeting imaging agent to detect residual cancer in real time during surgery — directly comparable mechanism and breast-cancer surgical use case as Blaze's Tumor Paint.
  • Perimeter Medical Imaging AI: Perimeter develops wide-field optical coherence tomography and AI-driven image analysis for intraoperative margin assessment in breast-conserving surgery — competing in the same clinical workflow that Blaze's Tumor Paint targets.

Emerging players

  • Avelas Biosciences: Avelas is developing fluorescent imaging agents for cancer surgery visualization, paralleling Blaze's Tumor Paint approach with a focus on tumor-targeted intraoperative fluorescence.

Broad incumbents

  • Stryker: Stryker acquired Novadaq and now markets the SPY fluorescence imaging platform used in surgical visualization, making it a broad incumbent in intraoperative fluorescence imaging overlapping Blaze's clinical setting.
  • Karl Storz: Karl Storz is a leading endoscopy and surgical imaging vendor with near-infrared fluorescence capabilities integrated into its visualization platforms — overlapping Blaze's intraoperative imaging use cases.
  • Carl Zeiss Meditec: Zeiss Meditec supplies surgical microscopy and intraoperative fluorescence imaging solutions, including for neurosurgical oncology workflows directly comparable to tozuleristide's CNS tumor application.
  • Medtronic: Medtronic is a broad neurosurgery and surgical-tools incumbent with imaging-adjacent offerings relevant to the CNS tumor resection setting Blaze targets with its pediatric CNS pivotal program.

Others

  • Leica Microsystems (Danaher): Leica manufactures surgical and fluorescence microscopy platforms used in operating-room visualization, making it an adjacent enabling technology provider to Blaze's intraoperative imaging approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Blaze Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blaze Bioscience leadership team

Management profile

Number of profiles

Profiles12 records

Blaze Bioscience funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blaze Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blaze Bioscience

What does Blaze Bioscience do?

Blaze Bioscience develops and is commercializing Tumor Paint®, an investigational fluorescent imaging agent (tozuleristide / BLZ-100) that conjugates a scorpion-derived chlorotoxin peptide with indocyanine green (ICG) to make tumor tissue fluoresce under near-infrared light during surgery. The drug is administered to patients prior to surgery and visualized intraoperatively using the company's CANVAS® real-time fluorescence imaging system, allowing oncology surgeons to distinguish malignant tissue from healthy tissue, identify residual cancer on cavity walls, and improve achievement of clear margins in procedures such as breast-conserving surgery, brain tumor resection, and other solid-tumor operations.

Is Blaze Bioscience a public or private company?

Blaze Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Blaze Bioscience founded?

Blaze Bioscience was founded in 2010. It employs 11 to 50 people.

Where is Blaze Bioscience based?

Blaze Bioscience is headquartered in Seattle, United States, in the North America region.

How does Blaze Bioscience make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are technology Licensing.

Who are Blaze Bioscience's main competitors?

Direct peers on record are Lumicell and Perimeter Medical Imaging AI. Avelas Biosciences is listed as an emerging player. Broad incumbents are Stryker, Karl Storz, Carl Zeiss Meditec and Medtronic. Leica Microsystems (Danaher) is listed as an others.

Does Blaze Bioscience have an API?

No public API is recorded for Blaze Bioscience.

What industry is Blaze Bioscience in?

Blaze Bioscience's product category is Surgical Oncology Imaging. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAKAFAG, Surgical Oncology. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GeekWireBlaze Bioscience gets Fast Track approval from FDA for ‘Tumor Paint’ that helps remove brain tumorsBlaze Bioscience received Fast Track designation from the FDA for tozuleristide, a synthetic peptide known as 'Tumor Paint' designed to help surgeons remove brain tumors. The company is currently evaluating the treatment in a phase 2/3 clinical trial with pediatric patients. This designation aims to expedite the approval process for addressing pediatric brain tumors, which are the leading cause of cancer-related death among children and adolescents.GeekWireSeattle startup Blaze Bioscience makes brain tumors ‘light up like a Christmas tree’ in first trialSeattle-based biotech company Blaze Bioscience successfully completed its first clinical trial for BLZ-100, a fluorescent 'tumor paint' designed to help surgeons identify and remove brain tumor cells. The phase 1 study involving 17 adult glioma patients demonstrated the technology's safety and efficacy in highlighting tumors without serious adverse effects. Following this success, the company is advancing to pediatric trials at 14 sites across the United States.GeekWireHow scorpion venom helps improve brain cancer surgery in children by making tumors glowBlaze Bioscience raised $5 million to advance its Tumor Paint, a molecule that lights up brain tumors for surgeons. The company is testing it on children with central nervous system tumors at Seattle Children's Hospital, where it enrolled its first patient last fall. The trial aims to expand to 114 patients across 14 sites this year.FierceBiotechBlaze Bioscience kicks off pivotal trial for brain tumor-illumination techBlaze Bioscience enrolled the first patient in a phase 2/3 trial of its scorpion-venom-based tumor paint BLZ-100, which illuminates brain tumors for surgeons. The trial will enroll 114 patients across 15 U.S. sites to test safety and efficacy of the fluorescent molecule and the Canvas Imaging System.Fred HutchGood News: CBS 'Sunday Morning' to feature Dr. Jim Olson's Tumor Paint research this weekendFred Hutchinson Cancer Research Center will feature Dr. Jim Olson's Tumor Paint research on CBS 'Sunday Morning', highlighting the investigational product derived from scorpion venom that distinguishes cancer from healthy tissue. The center has licensed the technology to Blaze Bioscience, with both entities holding ownership interests in the company developing the treatment. Additionally, three Fred Hutch groups received a total of $800,000 in grants from amfAR to investigate HIV cure approaches using cell and gene therapies.KVALScorpion venom leads local doctors to cancer breakthroughBlaze Bioscience received FDA approval to begin human clinical trials for its experimental cancer-detecting compound, known as tumor paint, which is derived from scorpion venom. The trial will involve 21 brain cancer patients in the U.S. and Australia to evaluate the compound's ability to help surgeons identify malignant tissue during surgery. This milestone follows years of development funded by community fundraising after initial grant applications were rejected.Fred HutchTumor Paint approved for first U.S. trialThe U.S. Food and Drug Administration has approved an investigational new drug application for Tumor Paint BLZ-100, allowing Blaze Bioscience Inc. to proceed with a clinical trial in the United States. The Phase 1 study will enroll twenty-one adult patients at sites in California and Australia to test the safety of the scorpion venom-derived dye that highlights cancer cells during surgery.FinSMEsBlaze Bioscience Raises $9M in Series B FinancingBlaze Bioscience raised $9M in Series B financing, bringing total funds to $19M. The company will use the funds for clinical development of its Tumor Paint product candidate BLZ-100 and Optide drug candidates under a collaboration with Fred Hutchinson Cancer Research Center.GeekWireTumor paint startup Blaze Bioscience raises $9M to help surgeons pinpoint cancer cellsBlaze Bioscience raised $9 million from individual investors, bringing total funding to $19 million. The Seattle spinoff will use the funds to develop BLZ-100, a product designed to help surgeons pinpoint cancer cells in real time. The company says the technology could treat multiple forms of cancer.GeekWireBlaze Bioscience raises $8.5M to help surgeons pinpoint cancer cells with ‘tumor paint’Blaze Bioscience raised $8.5 million in a Series A round from individual investors, bringing total funding to $9.8 million. The Seattle biotech's Tumor Paint technology uses a targeting peptide and fluorescent beacon to help surgeons identify cancer cells. The company is entering Phase 1 clinical trials to assess safety in cancer patients.